RISK MANAGEMENT STRATEGIES FOR REDUCING ORAL ADVERSE DRUG EVENTS

被引:5
|
作者
Spolarich, Ann Eshenaur [1 ,2 ]
机构
[1] USC, Div Dent Publ Hlth & Pediat Dent, Ostrow Sch Dent, Los Angeles, CA 90089 USA
[2] USC, Natl Ctr Dent Hyg Res & Practice, Ostrow Sch Dent, Los Angeles, CA 90089 USA
关键词
Oral adverse drug events; xerostomia; drug-induced ulceration; mucositis; lichenoid drug reaction; CLINICAL-PRACTICE GUIDELINES; SALIVARY-GLANDS; ANTIMICROBIALS; AGENTS;
D O I
10.1016/j.jebdp.2014.04.009
中图分类号
R78 [口腔科学];
学科分类号
1003 ;
摘要
Oral adverse drug effects negatively impact oral health, comfort and function. Background Patients treated in the oral health care environment take multiple medications, many of which cause oral complications. Dental professionals are challenged with making recommendations to prevent or minimize drug-induced oral disease risks, while reducing symptoms to improve oral health quality of life. Methods This paper presents a critical analysis of current evidence regarding common oral adverse drug events, and reviews existing clinical practice guidelines based upon findings from published systematic reviews. Results There is a lack of sufficient, high quality evidence to support most recommendations for interventions to relieve signs and symptoms of drug-induced oral adverse events. Existing recommendations are largely based on data obtained from observational studies and case reports, and from randomized controlled clinical trials with significant design flaws and potential reporting bias. Outcome measures, especially those related to symptom relief and long-range benefits, are either insufficient or lacking. Conclusions Oral adverse drug effects are a common problem, and additional data is needed to support best practices for product recommendations to improve oral health in medicated patients.
引用
收藏
页码:87 / +
页数:9
相关论文
共 50 条
  • [1] Reducing the Risk of Adverse Drug Events in Older Adults
    Pretorius, Richard W.
    Gataric, Gordana
    Swedlund, Steven K.
    Miller, John R.
    [J]. AMERICAN FAMILY PHYSICIAN, 2013, 87 (05) : 329 - 334
  • [2] Reducing adverse drug events by targeting at-risk patients
    Lowery, Mark
    [J]. FORMULARY, 2013, 48 (10) : 316 - 316
  • [3] Management of adverse drug events
    Jaehde, U.
    [J]. EJC SUPPLEMENTS, 2009, 7 (02): : 75 - 76
  • [4] Adverse Drug Events in the Oral Cavity
    Yuan, Anna
    Woo, Sook-Bin
    [J]. DERMATOLOGIC CLINICS, 2020, 38 (04) : 523 - 533
  • [5] Adverse drug events in the oral cavity
    Yuan, Anna
    Woo, Sook-Bin
    [J]. ORAL SURGERY ORAL MEDICINE ORAL PATHOLOGY ORAL RADIOLOGY, 2015, 119 (01): : 35 - 47
  • [6] Pharmacogenomics and reducing the frequency of adverse drug events
    O'Kane, DJ
    Weinshilboum, RM
    Moyer, TP
    [J]. PHARMACOGENOMICS, 2003, 4 (01) : 1 - 4
  • [7] Multifaceted approach to reducing preventable adverse drug events
    Silverman, JB
    Stapinski, CD
    Churchill, WW
    Neppl, C
    Bates, DW
    Gandhi, TK
    [J]. AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2003, 60 (06) : 582 - 586
  • [8] Identifying high risk patients for pain management strategies aimed at reducing postsurgical opioid-related adverse events.
    Nipper-Johnson, Kathy
    Minkowitz, Harold
    Scranton, Richard
    Shah, Manan
    Raju, Aditya
    Gruschkus, Stephen K.
    [J]. PHARMACOTHERAPY, 2013, 33 (10): : E243 - E243
  • [9] Reducing harms: Focus on drug-drug interactions and adverse drug events
    Citrome, Leslie
    [J]. INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2017, 71 (10)
  • [10] Detecting and reducing hospital adverse events: outcomes of the Wimmera clinical risk management program
    Wolff, AM
    Bourke, J
    Campbell, IA
    Leembruggen, DW
    [J]. MEDICAL JOURNAL OF AUSTRALIA, 2001, 174 (12) : 621 - 625